National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
Pharmacol Res Perspect. 2021 May;9(3):e00730. doi: 10.1002/prp2.730.
Atorvastatin and direct oral factor Xa inhibitors (xabans) are frequently co-administrated in patients with atrial fibrillation (AF). However, no studies investigating the possibility of the pharmacologic interaction between these agents have been conducted. The aim of this prospective observational study was to determine the impact of atorvastatin therapy on anti-Xa activity in xabans-treated patients with AF. We enrolled 115 AF patients on long-term rivaroxaban (52 patients) and long-term apixaban (63 patients) therapy. Long-term atorvastatin (40 mg once daily) was administrated to 28 rivaroxaban-treated patients and to 28 apixaban-treated patients. Trough and peak samples were tested for anti-Xa activity with drug-specific anti-Xa chromogenic analysis. For rivaroxaban, there were no significant differences in trough activity (45.5 ± 39.5 ng/ml vs. 46.2 ± 30.1 ng/ml; p = .34) and peak anti-Xa activity (179.2 ± 108.8 ng/ml vs. 208.1 ± 104.1 ng/ml; p = .94) between atorvastatin-treated patients and those without atorvastatin. Similarly, atorvastatin did not impact the trough activity (127.7 ± 71.1 ng/ml vs. 100.8 ± 61.1 ng/ml; p = .12) or peak anti-Xa activity (213.8 ± 103.6 ng/ml vs. 179.3 ± 72.9 ng/ml; p = .14) among apixaban-treated patients with AF. This observational study did not show a significant impact of atorvastatin on trough and peak anti-Xa activity in xabans-treated patients with AF.
阿托伐他汀和直接口服因子 Xa 抑制剂（沙班类药物）经常同时用于房颤（AF）患者。然而，目前尚未开展研究来评估这两种药物之间是否存在药物相互作用。本前瞻性观察性研究旨在确定阿托伐他汀治疗对沙班类药物治疗的 AF 患者抗-Xa 活性的影响。我们纳入了 115 例长期接受利伐沙班（52 例）和长期接受阿哌沙班（63 例）治疗的 AF 患者。28 例利伐沙班治疗患者和 28 例阿哌沙班治疗患者接受了长期阿托伐他汀（40mg 每日一次）治疗。采用药物特异性抗-Xa 显色分析检测抗-Xa 活性的谷值和峰值样本。对于利伐沙班，阿托伐他汀治疗组与未用阿托伐他汀治疗组的谷值活性（45.5±39.5ng/ml 比 46.2±30.1ng/ml；p=0.34）和峰值抗-Xa 活性（179.2±108.8ng/ml 比 208.1±104.1ng/ml；p=0.94）均无显著差异。同样，阿托伐他汀对阿哌沙班治疗的 AF 患者的谷值活性（127.7±71.1ng/ml 比 100.8±61.1ng/ml；p=0.12）或峰值抗-Xa 活性（213.8±103.6ng/ml 比 179.3±72.9ng/ml；p=0.14）也无显著影响。本观察性研究未显示阿托伐他汀对沙班类药物治疗的 AF 患者的谷值和峰值抗-Xa 活性有显著影响。
